[The antihypertensive and antianginal activity of Dilren--a prolonged-action calcium antagonist].
A 4-week course of dilren under clinical, bicycle exercise, ECG, echo-CG control and 24-hour monitoring of AP was given to 19 subjects with essential hypertension stage I-II and ischemic heart disease. A single dose of the drug (300 mg/day) diminished hypertension and angina pectoris in 79 and 63% of the patients, respectively. A 4-week dilren produced a 10-11% decrease in the total peripheral vascular resistance, prolonged P-Q interval by 0.01-0.02 sec without atrioventricular block in 26% of the patients, reduced AP measured according to Korotkov by 14.2/10.5 mm Hg (in awake patients by 12.8/8.4 mm Hg, in sleeping ones by 8.6/4.5 mm Hg without changes in 24-h AP curve). Side effects occurred in 5.3% of the cases and were overcome without discontinuation of the treatment.
Ol'binskaia
L I
LI
Vartanova
O A
OA
Khapaev
B A
BA
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004110:Diltiazem
Antigipertenzivnaia i antianginal'naia aktivnost' dilrena--antagonista kal'tsiia prolongirovannogo deĭstviia.